Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. The company has a collaborative research partnership with Astellas Pharma Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ALPMY
CUSIPN/A
Phone813-3244-3000
Debt
Debt-to-Equity Ratio0.03%
Current Ratio2.34%
Quick Ratio1.97%
Price-To-Earnings
Trailing P/E Ratio17.50
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.13 billion
Price / Sales2.49
Cash Flow$1.1949 per share
Price / Cash12.21
Book Value$5.27 per share
Price / Book2.77
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$1.95 billion
Net Margins14.70%
Return on Equity14.40%
Return on Assets10.12%
Miscellaneous
EmployeesN/A
Outstanding Shares2,068,820,000
